Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/34230
Title: | Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats |
Authors: | Aksit, Dilek Yalinkilinc, Hande Sultan Sekkin, Selim Boyacioglu, Murat Ayaz, Erol Gokbulut, Cengiz Uludağ Üniversitesi/Veteriner Fakültesi/Klinik Öncesi Bilimler Bölümü. 0000-0003-0570-2514 Cirak, Veli Yilgor FYC-2043-2022 6602404057 |
Keywords: | Veterinary sciences Benzimidazoles Albendazole Albendazole sulfoxide Pharmacokinetics Enantiomers Sheep Goat Dairy goats Enantiomers Ricobendazole Metabolites Fenbendazole Oxfendazole Netobimin Behavior Pharmacology Formulation Benzimidazoles Sheep Animalia Capra hircus Ovis aries |
Issue Date: | 12-Dec-2015 |
Publisher: | BMC |
Citation: | Aksit, D. vd. (2015). "Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats". BMC Veterinary Research, 11(1) |
Abstract: | Background: The aims of this study were to compare the pharmacokinetics of albendazole sulfoxide (ABZ-SO, ricobendazole) in goats and sheep at a dose of 5 mg/kg bodyweight (BW), after intravenous (IV) and subcutaneous (SC) administrations, and to investigate the effects of increased doses (10 and 15 mg/kg BW) on the plasma disposition of ABZ-SO in goats following SC administration. A total of 16 goats (Capra aegagrus hircus, eight males and eight females) and 8 sheep (Ovis aries, four males and four females) 12-16 months old and weighing 20-32 kg, were used. The study was designed according to two-phase crossover study protocol. In Phase-1, eight sheep were assigned as Group I and 16 goats were allocated into two groups (Group II and Group III). ABZ-SO was applied to Group I (sheep) and Group II (goats) animals subcutaneously, and to Group III (goats) animals intravenously, all at a dose rate of 5 mg/kg BW. In Phase-2, the sheep in the Group I received ABZ-SO intravenously in a dose of 5 mg/kg BW; the goats in Group II and Group III received ABZ-SO subcutaneously at a dose of 10 mg/kg and 15 mg/kg BW, respectively. Blood samples were collected from the jugular vein at different times between 1 and 120 h after drug administrations. The plasma concentrations of ABZ-SO and its metabolites were analysed by high performance liquid chromatography. Results: In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of 5 mg/kg BW. On the other side, dose-dependent plasma dispositions of ABZ-SO were observed following SC administration at increased doses (10 and 15 mg/kg) in goats. Conclusions: Consequently, ABZ-SO might be used at higher doses to provide higher plasma concentration and thus to achieve greater efficacy against the target parasites. |
URI: | https://doi.org/10.1186/s12917-015-0442-5 https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-015-0442-5 http://hdl.handle.net/11452/34230 |
ISSN: | 1746-6148 |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.